NVAX - 3 COVID Stocks That Will Make Billions in 2022
It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.
Pfizer (NYSE: PFE) , the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax (NASDAQ: NVAX) is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology (NASDAQ: VIR) . It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.
Image source: Getty Images.
For further details see:
3 COVID Stocks That Will Make Billions in 2022